Oxurion NV — Major Shareholding Notification 2025

Jan 14, 2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – January 3, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on December 30, 2024, from Atlas Special Opportunities, LLC indicating that as of December 30, 2024, it held 35,039 shares of the then outstanding 2,567,406 shares, and therefore crossed under the threshold (3%) by virtue of the sale of voting securities.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA	FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
1) Status of the notification
	Final
2) Issuer
ldentification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights Downward crossing of the lowest threshold
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name	Address (for legal entities)
	Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577
	6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
	Name	Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6	Part II
7) Date on which the threshold is crossed
		30/12/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
	3
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
	2,567,406
10) Notified details
A) Voting rights	Previous notification	After the transaction
	# of voting rights	# of voting rights	% of voting rights

	a) voung nyms	Cleving Illumination
		# of voting rights	# of voting rights		% of voting rights
	Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
	Atlas Special Opportunities LLC	331.543	35.039		1.36%
TOTAL		35.039		1.36%

Start with "groups" of holders. Add subtotals with Z, and the finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or leg

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL
C The totals will be updated once you have clicked on
	TOTAL (A & B)			# of voting rights	% of voting rights
			CALCULATE	35,039	1.36%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.
12) In case of proxy voting for only one GM	(DD/MM/YYYY)
will cease to hold / 0 Holder voting rights as of will hold again
13) Additional information
On 11 December 2024 (with setter end deal Opertunities LC sold 6,979 shares in Oxunon N', as a result of which its shareholding decreased to 24,54 shares (= 12.64%, denominator = 2,567,406). On 13 December 2024 (with setter 2024), Alas Special Opprtunities LC sold 6,00 shares in Oxinon NY, as a result of which its shares in 318,54 shares (= 12.41%, denominator = 2,567,406). On 24 December 2024 (with settement date on 30 December 2024), Mas Special Opportunities LC sold of Wrich its starebolding decreased b 3,039 shares = 1.36%, denominator = 2,567,406).
Done at New York
30/12/2024 (DD/MM/YYYY) On
Signed by Name & capacity Patrick Vance, Proxyholder Patrick Varie Signature 9A8C4789B05442E

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in PDE format should also be
transmitted.